series-b
Stage
1
Investors
About
Diagonal Therapeutics develops multispecific clustering antibody therapeutics that target dysregulated cellular signaling pathways to treat and potentially modify the underlying causes of genetic and chronic diseases.
Explore Diagonal Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.